Cortechs.ai | Cortechs.ai licenses technology patents from the University of California San Diego (UCSD)

Cortechs.ai licenses technology patents from the University of California San Diego (UCSD)

Technology derived from UCSD researchers to further develop new volumetric imaging products     

(SAN DIEGO) September 11, 2019 – Cortechs.ai, the leader in AI-based brain image quantification, has announced that it has entered into licensing agreements with the University of California San Diego (UCSD), allowing the company to utilize several technologies focused on expanding the role of volumetric magnetic resonance imaging (MRI) in clinical practice.

“These technologies out-licensed from UCSD significantly expand our IP portfolio and will contribute to further development of our flagship product, NeuroQuant® as well as more broadly grow our quantitative MRI focused product lines,” said Dr. Chris Airriess, CEO of Cortechs.ai. “We are excited about the improvements these new technologies will bring to radiology workflow and, most importantly, to patient care in general.”

The technologies licensed from UCSD will allow Cortechs.ai to utilize the specific systems, methods, and software needed to better quantify communications pathways within the brain as well as accurately pinpoint regions of pathology as part of an automated processing stream. Technologies ready for implementation and sub-licensing include advanced techniques for image distortion correction due to magnetic field inhomogeneities, as well as active correction for patient movement in the scanner, which is critical for imaging of some patient populations.

These in-licensed technologies will help Cortechs.ai drive the ongoing evolution of current flagship products, NeuroQuant, LesionQuant™ and PETQuant™, as well as partner with other companies to bring novel AI-based solutions to the volumetric imaging space.

About Cortechs.aiCortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists and clinical researchers worldwide with a convenient and cost-effective means to quantify brain structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development abnormalities. Please visit cortechs.ai for further information and follow us on Twitter, LinkedIn and Facebook.

###

 

More Resources

09/03/2025

Reimbursement Considerations for OnQ Prostate and Category III CPT Codes 0648T & 0649T

Learn how Cat. III CPT codes 0648T and 0649T apply to OnQ™ Prostate, offering guidance for accurate reporting, reimbursement, and building evidence for coverage

09/02/2025

Maximizing the Value of Prostate MRI for the Urologist

Even with expert radiologists or AI models at hand, the challenge remains: how can urologists improve seeing and interpreting cancer?

08/18/2025

Why Bigger Normative Databases Mean Better Brain Imaging

NeuroQuant® 5.2 compares patient brain MRI volumes to over 7,000 healthy scans, giving clinicians clear, percentile-based context for better assessments.

08/07/2025

Navigating Reimbursement for NeuroQuant: Understanding CPT Codes 0865T & 0866T 

Let’s break down the latest category III CPT codes and example clinical use cases that illustrate their value.

07/31/2025

Precision Without the Pressure: Smarter Brain Tumor Monitoring

Learn about NeuroQuant Brain Tumor 2.0 and how it assists clinicians by providing objective quantification and analysis of tumor changes over time.

07/30/2025

Cortechs.ai Announce Next-Gen NeuroQuant Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation 

NeuroQuant Brain Tumor is the first FDA-cleared, cloud-native tool to offer automated volumetric segmentation for brain metastases, meningiomas, and gliomas.
Scroll to Top